Building S12: By the Numbers

Total Square Footage: 135,000

Projected Time for Renovation (in Months): 30

Actual Time of Phase 1 Renovation (in Months): 9

Number of Contractors: 700+

Lost Time Incidents (More than 100,000 Man-Hours): 0

Tons of Stainless Steel Used in Tables of Processing Areas: 14

Pounds of Sheet Metal Used in Ductwork: 302,000

Pieces of Equipment Qualified: 480

Total Budget (All Phases): $133 million

Celgene recently completed the first phase of renovations for Building S12 on the company’s western campus in Summit, New Jersey. By converting S12 from office space to a state-of-the-art cellular immunotherapy manufacturing facility, Celgene will have the capability to expand its investigational studies of bb2121 – a CAR T therapy being developed in conjunction with our partner, bluebird bio, for the treatment of certain patients with Relapsed/Refractory Multiple Myeloma (RRMM).

CAR T therapy engages a patient’s own immune system in the fight against cancer. We believe that bb2121 has the potential to create significant impact on the treatment approach and outcomes for certain patients with RRMM. The Building S12 renovation demonstrates our full commitment to the investigation of CAR T therapies such as bb2121. As such, the facility has been designed with a modular approach, making it adaptable to future, potentially disruptive cellular immunotherapy products and technological platform innovations.

Celgene expects to hire hundreds of new employees for Building S12 over the next three years. The conversion of Building S12 confirms Celgene’s long-term commitment to both the local economy of the City of Summit and to the overall infrastructure for science, medicine and innovation in the State of New Jersey – as well as reflecting our ongoing commitment to improving the lives of patients worldwide.

Note: bb2121 is an investigational compound that is not approved for any use in any country.